CYTORI THERAPEUTICS (NASDAQ: CYTX)

Sector: Medical

Current Price : $2.53

52 Week Low
$2.0452 Week High
$4.75

Press Releases
Cytori to Present at Regen Med Investor Day 2013 on April 17
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013
Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells
Cytori Provides Update in 510(k) Appeal Decision
Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7
Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer
Intravase? Approval Opens Vascular Market for Cytori
Cytori Therapeutics Prices $20.0 Million Public Offering of Common Stock
Cytori Therapeutics Proposes Public Offering of Common Stock
Cryptoglandular Fistula Repair Case Series Using Cytori Cell Therapy Published in the British Medical Journal: Case Reports
Stem Cell Stocks Gaining Popularity in 2012 as a Result of Breakthroughs in Research
Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum on October 30
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan
Investigator-Sponsored Cell Therapy Clinical Study for Scleroderma Initiated in France
Multiple miRNA Markers Associated with Angiogenesis and Tissue Injury Repair Expressed in Cytori's Cell Therapy
Cytori Awarded Contract Valued up to $106 Million by Biomedical Advanced Research and Development Authority (BARDA) to Develop Cell Therapies for Thermal Burns Combined with Radiation Injury
Cytori Expands European Approval for Celution(R) System for New Indications, Including Intractable Cryptoglandular Fistulae; Investigator-Sponsored Fistula Repair Study Initiated in Japan
Cytori Provides Business Update and Reports Second Quarter and First Half 2012 Results
Despite Global Economic Slowdown Biotech Industry Soaring in 2012
Cytori to Webcast Second Quarter Financial Results on August 8
Cytori Obtains Celution(R) Approval in Russia; To Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies
Cytori to Present at the Jefferies 2012 Global Healthcare Conference on June 5
Cytori Provides Business Update; Reports First Quarter Results
Cytori to Webcast First Quarter Financial Results May 9
Ruling in Texas Could Provide New Opportunities for Stem Cell Companies
Cytori Breast Reconstruction Cell Therapy Trial Results Published
FDA Grants Cytori 510(k) Clearance for Puregraft(R) 850
Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results
Cytori to Webcast Year End Financial Results March 8
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution(R) System
Cytori's Celution(R) One Receives European CE Mark Approval
Advanced Cell Technology and Cytori Therapeutics Gain Support as Geron Changes Strategy
Cytori Therapeutics Announces Participation in the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum
Cytori to Webcast Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011
Cytori Reports Third Quarter Business Update and Financial Results
Cytori to Webcast Third Quarter Financial Results November 3
Stem Cell Research Mired in Controversy -- Again
Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement
Cytori Amends and Expands Credit Facility Led by GE Capital, Healthcare Financial Services
CEO Chris Calhoun to Present Corporate Report at Cytori Annual Shareholder Meeting on August 16
Cytori to Webcast Second Quarter Financial Results August 9 and Annual Shareholder Meeting on August 16
Cytori Completes Equity Agreement; Funding to Support ADVANCE Clinical Trial & Other Corporate Initiatives
Maven Semantic: Regenerative Medicine Database
Speculative Stem Cells Stocks Prepared to Pay Off
Cytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart Attack Trial
NHS National Innovation Centre Identifies Celution(R) as Cost-Effective Innovative Technology for Partial Breast Reconstruction
Urinary Incontinence Study Using the Celution(R) System Approved in Japan
Cytori to Present at the Jefferies 2011 Global Healthcare Conference on June 8
Cytori Therapeutics Announces Independent Clinical Study Results in Breast Reconstruction Presented at the Association of Breast Surgery Conference
Cytori Announces Clyde W. Shores as Executive Vice President of Marketing & Sales
Cytori Provides Update on Product Pipeline Developments and Reports First Quarter Results
Cytori's StemSource(R) Cell Bank to Be Installed for Neo Derm in Hong Kong
Cytori Appoints Tommy G. Thompson to its Board; Names Lloyd Dean Chairman
Cytori to Webcast First Quarter Financial Results on May 5
NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 15, 2011
Maven Semantic: Adipocyte Research Database
Cytori Patents Method of Making Stem and Regenerative Cell-Enriched Fat Grafts
New Breast Reconstruction Procedure Demonstrates Long Term Success in European Trial; Data Reported From Cytori's RESTORE-2 Study of the Celution(R) System
Cytori to Webcast Corporate Presentation at CitiBank Global Healthcare Conference on March 2 Followed by Fourth Quarter Earnings on March 10
Sound Surgical Technologies to Promote Cytori's PureGraft(TM) System -- the Latest Innovation in Fat Grafting
Fat Grafting Safety Review Published; Clinical Experience Shows No Increased Risk of Cancer in Fat Grafting Patients
Adipose-Derived Regenerative Cell (ADRC) Therapy Associated With Reduction in Arrhythmia in Acute Heart Attack Patients; Post-Hoc Data From Cytori's APOLLO Study Reported at the 6th International Conference on Cell Therapy for Cardiovascular Disease
Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe; First ADVANCE Trial Site to Begin Enrollment in the Netherlands
Cytori Announces January Conference Schedule

iStock Rating

CYTORI THERAPEUTICS (NASDAQ: CYTX)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios